Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Biochemical Insights into Progeria Syndrome Identify Bisphosphonates, Statins as Possible Candidate Drugs to Halt Aging

Simon M. Helfgott, MD  |  Issue: August 2016  |  August 10, 2016

One of these children attended my kids’ elementary school, where his name is memorialized in the school library.2

Recent biochemical insights into progeria have identified some candidate drugs that may effectively metabolize progerin and displace it from the nuclear membrane. Interestingly, these include two widely prescribed agents used to halt certain effects of aging, bisphosphonates and statins.3 Although they appear to provide some benefit, they have not remedied the predicament of progeria.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This raises the question: Can aging be halted?

The solution to this vexing question would not only improve the lives of children with progeria, it would have the potential to dramatically alter society as a whole and profoundly disrupt the practice of medicine. Imagine a world where those diseases that rob us of our youth and grace disappear, where heart disease is rarely seen, where the hazards of osteoarthritis disappear and eliminate the need for joint arthroplasty, or where the incidence of neurodegenerative diseases declines precipitously, forcing nursing homes to shutter.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Skin Deep

Smetek / Science Source.com

Smetek / Science Source.com

We are nowhere near achieving these targets. In the interim, countless pills and minerals of questionable benefit crowd the anti-aging space. And of course there is one faux remedy for aging, a deadly poison turned dermatologists’ best friend—botulinum toxin A. This neurotoxin was best known as the highly lethal protein capable of paralyzing those ingesting it. Taming the botulinum toxin’s paralyzing effects led to it first being used in the neurology clinic, where its benefits in reducing muscle spasticity were readily apparent. Soon afterward, it migrated to the ophthalmologist’s chair, where it gained acceptance as a highly effective treatment for another spastic disorder, blepharospasm.

For years, it languished as a novel product for a niche market until the serendipitous discovery that when used to treat spastic eyelids, it also smoothed any nearby crow’s feet or under-eye wrinkles. For some of these patients, it seemed to turn back the clock. Quel visage! The toxin has acquired a growing list of clinical indications, ranging from migraine headache relief to managing overactive bladder function to relieving the spastic vascular supply in fingers afflicted by Raynaud’s phenomenon. Yet botulinum toxin’s greatest use remains cosmetic, magically creating a mirage—altering appearances.

If we are going to reverse the aging process, we need to better understand what is happening deep inside our cells. What actually causes us to age?

Vino Vivo

If we are going to reverse the aging process, we need to better understand what is happening deep inside our cells. What actually causes us to age? One of the most plausible explanations for the mechanistic basis of aging is the mitochondrial free radical theory of aging, which argues that aging and its related diseases are the consequence of free radical-induced damage to cellular macromolecules and the inability to counterbalance these changes by endogenous antioxidant defenses.4

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Career DevelopmentEducation & TrainingProfessional TopicsResearch Rheum Tagged with:agingbisphosphonatesClinicalDrugspatient careResearchrheumatologyStatintherapy

Related Articles

    What Mick Jagger Can Teach Us About Growing Old Gracefully

    February 1, 2013

    Preventive lifestyle behaviors, including regular exercise, can compress morbidity and disability to the very end of our lives, say rheumatologists

    Anti-Mitochondrial Antibodies & Systemic Lupus Erythematosus

    April 29, 2019

    Although antimitochondrial antibodies are present in SLE patients, researchers have has difficulty investigating the phenomenon due to barriers in isolating pure mitochondria. The study describes a technique that allows for such an investigation and provides insight into how the adaptive immune system recognizes mitochondrial organelles…

    Diagnosis: Myopathy

    July 1, 2009

    Presentation and evaluation of metabolic causes

    New Insights into CPPD

    October 1, 2013

    Progress in research, outcomes, diagnosis, and treatment of calcium pyrophosphate dihydrate crystal deposition disease

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences